Business
Final Results
Final Results.
About this update from Genincode Plc
[{"type":"text","content":"\n\n \n4 June 2025\nGENinCode Plc\n(\"GENinCode\" or the \"Company\")\n \nFinal results\n \nOxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease (\"CVD\") and risk of ovarian cancer announces its audited final results for the twelve months ended 31 December 2024 (\"FY24\"). FY24 saw the Company introduce its novel polygenic tests to the US market and strengthen its commercial programme in the UK and Europe. \n \nFinancial and Operational highlights\n· Year on Year revenues increased 25% to £2.7m (2023: £2.2m), driven by volume growth in the UK and Europe\n· First US test revenues received for LIPID inCode® for the diagnosis of familial hypercholesterolemia (\"FH\") and CARDIO inCode® for the genetic risk of coronary artery disease (\"CAD\")\n· US Notice of Allowance (granted patent status) received for CARDIO inCode®\n· NHS expansion of LIPID inCode® for FH diagnosis in North of England\n· Growth of LIPID inCode® in University Clinic Dresden, Germany for primary care diagnosis of FH\n· CARDIO inCode® pilot launched in Extremadura, Spain\n· NICE recommendation for ROCA as preferred test for ovarian cancer surveillance\n· Reduced Year on Year Adjusted EBITDA loss of (£4.4m) (2023: loss of (£6.7m)) reflecting increased revenues and strengthening margins\n· Cash reserves of £1.1m at 31 December 2024 (2023: £2.5m)\n \nPost-period end\n· Successful completion of a £4.1m secondary placing to support scale up and commercialisation\n· CARDIO inCode® pilot launched in Catalunya region, Spain\n· CARDIO inCode® 'De Novo' progressive discussions to resolve deficiencies ongoing with Food and Drug Administration (FDA) for approval of CARDIO inCode® for prevention of coronary heart disease in the US\n· Inclusion of CARDIO inCode® in the 2025 Centers for Medicare and Medicaid Services (CMS) Clinical Lab Fee Schedule \n· NHS (UCL) adoption of Risk of Ovarian Cancer Algorithm (ROCA®) test for women at high risk of ovarian cancer\n \nCurrent trading and Outlook\n· For the first four months of FY25 consolidated revenues were 20% higher than same period in 2024\n· During 2025, ...